CCR2-64I gene polymorphism increase susceptibility to oral cancer
ABSTRACT The purpose of this study was to investigate the impact of MCP-1 and its receptor CCR2 gene polymorphisms on the susceptibility and clinicopathological characteristics of oral cancer, as well as the synergistic effect between these gene polymorphisms and well-known risk factors including alcohol, tobacco, and areca consumptions. Using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) technique for polymorphism analysis, 344 healthy controls and 216 oral cancer patients were recruited to reveal a significant association between V64I CCR2 gene polymorphism and oral cancer susceptibility. After adjusting for other confounders, individuals with GA (AOR=1.84; 95%CI=1.10-3.20) or at least one A allele (AOR=1.78; 95%CI=1.05-3.02) had a higher risk for oral cancer, compared to GG genotypes. Moreover, results also revealed that for subjects with GA or at least one A allele of V64I CCR2 gene polymorphism, those exposed to environmental risk factors possessed a significantly higher risk for oral cancer than those unexposed subjects. Therefore, genetic polymorphism of CCR2-64I may contribute to the susceptibility to oral cancer.
- SourceAvailable from: Fu-Qiang Wen
[Show abstract] [Hide abstract]
- "After HWE test, 3 articles (Saenz-Lopez et al., 2008; Attar et al., 2010; Gu et al., 2011) were deviated from HWE. Thus, a total of 11 case– control studies were extracted (Vazquez- Lavista et al., 2009; Narter et al., 2010; Yang et al., 2010; Yeh et al., 2010; Chen et al., 2011; Kruszyna et al., 2011; Kucukgergin et al., 2012a; Kucukgergin et al., 2012b; Bektas-Kayhan et al., 2012; Singh et al., 2012; Wu et al., 2013). The characteristics of each case–control study are listed in Table 1. "
ABSTRACT: Background: The 2518 A/G polymorphism in the MCP-1 gene has been extensively studied for association swith cancer; however, results from replication studies have been inconsistent. The aim of this investigation was to determine links with risk of cancer by meta-analysis. Methods: We searched Pubmed, Embase, CNKI, Weipu and Wanfang databases, covering all case-control studies until March, 2013. Statistical analyses were performed using the Revman 5.0 software. Results: A total of 11 case-control studies met our inclusion criteria, including 1,422 cases and 2,237 controls. The results indicated that the MCP-1 2518 gene polymorphism had no association with cancer risk overall (GG vs.GA+ AA: OR = 0.89, 95%CI = 0.61-1.28, P = 0.52). However, in the subgroup analysis by ethnicity, a decrease of cancer risk was found in Asian populations (GG vs.GA+ AA: OR = 0.79, 95%CI = 0.63-0.99, P = 0.04). Conclusion: This meta-analysis suggested that the 2518A/G polymorphism of MCP-1 gene is associated with risk of cancer among Asian, but not in Caucasian populations.Asian Pacific journal of cancer prevention: APJCP 06/2013; 14(6):3575-9. DOI:10.7314/APJCP.2013.14.6.3575 · 2.51 Impact Factor
- [Show abstract] [Hide abstract]
ABSTRACT: We aimed to investigate a possible association of the MCP-1 and CCR2 polymorphisms with the risk of developing oral squamous cell carcinoma (OSCC). MCP-1 A2518G and CCR2 V64I gene polymorphisms were performed by polymerase chain reaction and restriction fragment length polymorphism, in 129 patients with OSCC and 140 healthy control subjects. Individuals who had G allele and GG genotype of MCP-1, and 64I allele and wt/64I genotype of CCR2 had increased risk for OSCC (P<0.05.) In contrast, individuals with CCR2 wt/wt genotype seem to be protected from OSCC (P < 0.01). Haplotype analysis revealed that MCP-1G: CCR2 64I haplotype frequencies were significantly higher in patients than those of controls (P = 0.001). We can suggest that the G allele of MCP-1 and 64I allele of CCR2 may be risk factors for OSCC.Oral Diseases 07/2011; 18(1):55-9. DOI:10.1111/j.1601-0825.2011.01843.x · 2.40 Impact Factor
- [Show abstract] [Hide abstract]
ABSTRACT: The aim of our study was to determine the effect of monocyte chemotactic protein-1 (MCP-1), CC chemokine receptor 2 (CCR2), and CC chemokine receptor 5 (CCR5) gene polymorphisms on the susceptibility and clinicopathological characteristics of prostate cancer. Genotyping was performed by polymerase chain reaction (PCR)-restriction fragment length polymorphism (RFLP) method in 156 histopathologically confirmed prostate cancer patients and 152 healthy subjects. Individuals with AA genotype or at least one A allele of CCR2 V64I gene polymorphism had a higher risk for prostate cancer as compared with those with GG genotype (p=0.010 and p=0.028, respectively). CCR5 Δ32/wt genotype and CCR5 Δ32 allele were also found to be involved in the susceptibility to prostate cancer (p=0.028 and p=0.030, respectively). However, there was no significant association between MCP-1-2518 A/G gene polymorphism and prostate cancer risk. Prostate cancer patients carrying AA genotype or at least one A allele of CCR2 V64I had significantly increased risk for high stage disease (p=0.002 and p=0.039, respectively) and metastasis (p=0.004 and p=0.022, respectively). The CCR2 A allele (64I allele) was significantly associated with high T stage (p=0.001) and metastasis (p=0.005) as compared with CCR2 G allele (64V allele). Our data indicate that gene polymorphism of CCR2 V64I may influence the susceptibility and clinicopathological characteristics of prostate cancer and CCR5 Δ32 allele may also be an important risk factor for prostate cancer in Turkish men population.DNA and cell biology 05/2012; 31(8):1418-24. DOI:10.1089/dna.2012.1716 · 1.99 Impact Factor